Gilead and Novartis' cell therapies in trouble in the Danish Medicines Council
According to the Danish Medicines Council, neither Gilead Sciences nor Novartis provided enough documentation to obtain a recommendation of the companies' cell therapies against diffuse large B-cell lymphoma (DLBCL).
The rivals Gilead Sciences and Novartis have both run into problems with the Danish Medicines Council that is currently assessing the companies' cell therapies Yescarta and Kymriah against diffuse large B-cell lymphoma (DLBCL).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
